TMDX
TransMedics Group, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$89.98
+3.45%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
48.0x
EV/EBITDA
29.3x
Market Cap
$3.12B
MomentumView details →
1D Return
+3.45%
YTD Return
−28.18%
RSI (14)
52.7
ValuationView details →
P/E (Fwd)
48.0x
EV/EBITDA
29.3x
Market Cap
$3.12B
RSI (14)
52.7
MomentumView details →
1D Return
+3.45%
YTD Return
−28.18%
SummaryUpdated Jun 1, 2026
TransMedics Group, Inc. (NASDAQ:TMDX) is a commercial-stage medical technology company founded in 1998 and headquartered in Andover, Massachusetts. The company has transformed from a research-focused startup into a leading provider of organ preservation technology for transplant procedures. TransMedics went public in May 2019 and has since established itself as a key player in the organ transplantation market, operating primarily in the United States with expanding international presence. The company has experienced rapid growth, particularly following the launch of its National OCS Program (NOP) which provides comprehensive transplant logistics services.
Similar companies
Latest newsMore news →
Emerald Investment Advisers LLC acquired a new stake of 30,456 shares in TransMedics Group, Inc. during the quarter, valued at approximately $2,023,000, as disclosed to the SEC.13d agoTransMedics Group outlined its growth strategy at Canaccord Genuity's 46th Annual Global Growth Conference, highlighting investments in kidney transplantation, European expansion, next-generation technology, and broader adoption in heart and lung transplantation.18d ago